UKOF 2018 | Using immunotherapy wisely for prostate cancer
Gerhardt Attard
Only a small minority of prostate cancer patients benefit from immunotherapy. Gerhardt Attard, MD, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, spoke to us at the UK Oncology Forum (OF) 2018 in Liverpool, UK about the need for biomarker screening to determine which patients should be given immunotherapeutic agents. He discusses the NEPTUNES study (NCT03061539), which will select patients to receive a combination therapy of two immune checkpoint inhibitors according to a set of biomarkers: mismatch repair deficiency, defective DNA repair and a high inflammatory infiltrate level. The goal of this study is to accurately identify and treat the minority group of patients who will benefit from immunotherapy.
Similar topics
Related videos

Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles

Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa

Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen

TROPHY-U-01: Initial findings
Scott Tagawa

Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
More from Gerhardt Attard